US Patent Issued to City of Hope on Feb. 17 for "Targeted chimeric antigen receptor modified T cells for treatment of IL13RALPHA2 positive malignancies" (California Inventors)

ALEXANDRIA, Va., Feb. 17 -- United States Patent no. 12,551,557, issued on Feb. 17, was assigned to City of Hope (Duarte, Calif.).

"Targeted chimeric antigen receptor modified T cells for treatment of IL13RALPHA2 positive malignancies" was invented by Christine E. Brown (Duarte, Calif.), Xin Yang (Duarte, Calif.), Renate Starr (Duarte, Calif.), Wen-Chung Chang (Duarte, Calif.) and Stephen J. Forman (Duarte, Calif.).

According to the abstract* released by the U.S. Patent & Trademark Office: "Chimeric antigen receptors targeted to IL-13Ra2 are described. The targeting domain is a IL13 variant having increased specificity for IL-13Ra2 relative to IL-13Ra1."

The patent was filed on March 12, 2021, under Application No. 17/910,931.

*For furt...